Orlistat
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Orlistat |
| DrugBank ID | DB01083 |
| Brand Names (EU) | Xenical |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.46% |
Approved Indication (EMA)
Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors. Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | obesity disorder | 99.46% | DL |
| 2 | hypervitaminosis | 99.42% | DL |
| 3 | proximal 16p11.2 microdeletion syndrome | 98.87% | DL |
| 4 | obsolete hypertelorism (disease) | 97.75% | DL |
| 5 | frontorhiny | 96.64% | DL |
| 6 | hypoalphalipoproteinemia | 96.47% | DL |
| 7 | monogenic obesity | 94.45% | DL |
| 8 | obsolete susceptibility to ischemic stroke | 92.00% | DL |
| 9 | ABri amyloidosis | 85.67% | DL |
| 10 | fatty liver disease | 85.26% | DL |
| 11 | homozygous familial hypercholesterolemia | 79.84% | DL |
| 12 | amenorrhea (disease) | 77.89% | DL |
| 13 | non-alcoholic steatohepatitis | 77.14% | DL |
| 14 | hypercarotenemia and vitamin A deficiency, autosomal recessive | 71.03% | DL |
| 15 | lethal polymalformative syndrome, Boissel type | 68.51% | DL |
| 16 | duodenogastric reflux | 68.39% | DL |
| 17 | pentosuria | 68.26% | DL |
| 18 | duodenal obstruction | 68.11% | DL |
| 19 | fibrosis of extraocular muscles, congenital, with synergistic divergence | 66.92% | DL |
| 20 | mitral valve prolapse, myxomatous | 66.79% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.